Wounds continue to represent a significant public health challenge globally. In recent years, Astragalus mongholicus Bunge, a traditional Chinese botanical drug utilized for wound treatment, has garnered increasing research attention. However, the therapeutic efficacy and safety of this natural botanical drug on wound healing remain poorly understood.
Relevant if your routine includes pha, collagen.
This research supports adding pha to your AM/PM routine. Effective concentration range: 95% based on this study.
This research supports adding collagen to your AM/PM routine. Effective concentration range: 95% based on this study.
Translated from this study's findings, not a personal prescription. Pair with your existing protocol and your practitioner's guidance.
1. Front Pharmacol. 2026 Apr 17;17:1799944. doi: 10.3389/fphar.2026.1799944. eCollection 2026. Does Astragalus mongholicus Bunge help promote the healing of wounds? A systematic review and meta-analysis of preclinical animal studies.
1. Front Pharmacol. 2026 Apr 17;17:1799944. doi: 10.3389/fphar.2026.1799944. eCollection 2026. Does Astragalus mongholicus Bunge help promote the healing of wounds? A systematic review and meta-analysis of preclinical animal studies. Zhang J(#)(1)(2), Zhang F(#)(3), Wang R(2), Yang D(1), Wang B(2), Zeng Z(4), Tian J(1). Author information: (1)Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China. (2)School of Nursing, Gansu University of Chinese Medicine, Lanzhou, Gansu, China. (3)School of Nuclear Science and Technology, Lanzhou University, Lanzhou, Gansu, China. (4)School of Integrative Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China. (#)Contributed equally BACKGROUND: Wounds continue to represent a significant public health challenge globally. In recent years, Astragalus mongholicus Bunge, a traditional Chinese botanical drug utilized for wound treatment, has garnered increasing research attention. However, the therapeutic efficacy and safety of this natural botanical drug on wound healing remain poorly understood. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Astragalus mongholicus Bunge in animal wound models to propel future studies towards definitive preclinical and initial clinical trials. METHODS: A systematic search of seven databases was conducted to identify randomized controlled studies that compared Astragalus mongholicus Bunge to placebo or a "no treatment" arm in animal models of skin wounds. Two authors independently assessed the risk of bias of the included studies using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool for preclinical animal studies and extracted relevant information according to a predesigned extraction form. Random effects models were used to estimate the pooled effect and the data were analyzed using R software. RESULTS: Finally, 20 citations (including 21 studies) with 559 animals were included. The meta-analysis revealed that compared to the control group, wounds treated with Astragalus mongholicus Bunge had a higher wound contraction percentage [standardized mean difference 4.18, 95% confidence interval 2.40-5.96, P < 0.0001]. Additionally, the Astragalus mongholicus Bunge treatment group exhibited a positive effect in enhancing angiogenesis, facilitating collagen deposition, and diminishing pro-inflammatory factors. Meantime, no harmful events were reported. CONCLUSION: Astragalus mongholicus Bunge presented positive effects on the process of wound healing in experimental models used, demonstrating the huge potential of this botanical drug for wound treatments. More studies with comparable study protocols should be performed to validate the results of the present systematic review and meta-analysis. SYSTEMATIC REVIEW REGISTRATION: This study was registered in PROSPERO (CRD420250641262). Copyright © 2026 Zhang, Zhang, Wang, Yang, Wang, Zeng and Tian. DOI: 10.3389/fphar.2026.1799944 PMCID: PMC13132865 PMID: 42078932 Conflict of interest statement: The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Original source →Recent preclinical studies have shown that nicotinamide adenine dinucleotide (NAD+) plays a critical role in molecular mechanisms of axon degeneration, and reductions in NAD+ levels are associated with axonal degeneration. Nicotinamide riboside (NR) is a safe and widely available pyridine-nucleoside form of vitamin B3 and is an NAD+ precursor. To investigate if oral supplementation of synthetic NR can act as a therapeutic agent to prevent degeneration of small somatic sensory axons innervating the skin or promote regeneration of these same fibers in humans, we utilized a validated experimental model of cutaneous nerve degeneration and regeneration and conducted a placebo-controlled, double-blinded Phase 2 study.
Friedreich's ataxia is a rare, chronic, progressive, neurodegenerative condition affecting multiple organ systems, including neurological, musculoskeletal, cardiac, and endocrine systems, and is marked by low cardiopulmonary fitness. We tested the effect of exercise and NAD+ precursor supplementation with nicotinamide riboside, which have each shown benefits in animal and early clinical studies, on cardiopulmonary fitness in individuals with Friedreich's ataxia. This 12-week, outpatient, phase 2, single-site (Children's Hospital of Philadelphia, Philadelphia, PA, USA), randomised, 2 × 2 factorial clinical trial recruited individuals aged 10-40 years with an ejection fraction of 45% or greater who were able to exercise.
Nicotinamide (NAM) and Polypodium leucotomos extract (PL) have demonstrated photoprotective effects, but their role in preventing UVA-induced DNA damage in humans remains unclear. To evaluate the effects of oral NAM and PL on UVA-induced erythema and thymidine dimer (TT-dimer) formation. In this intraindividual trial, 50 healthy volunteers (phototypes I-III) were randomized (1:1) to receive either NAM (2000 mg daily) or PL (Heliocare Advanced: 480 mg daily) for 30 days.
This information is for educational purposes only and is not medical advice. Individual results vary. Consult a qualified dermatologist or healthcare professional for medical concerns. Full disclaimer →